How Emergency Departments Treat Cannabinoid Hyperemesis Syndrome

This review summarizes current pharmacological and non-pharmacological treatments for cannabinoid hyperemesis syndrome in the emergency department setting.

RTHC-07967ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

CHS management in the ED includes both pharmacological approaches (antiemetics, capsaicin) and non-pharmacological strategies (hot showers), with emergency pharmacists playing an increasingly important role in treatment decisions.

Key Numbers

Review article — synthesizes existing evidence on CHS treatments including pharmacological and non-pharmacological approaches.

How They Did This

Review article summarizing current evidence on pharmacological and non-pharmacological therapies for cannabinoid hyperemesis syndrome (CHS) in the emergency department.

Why This Research Matters

CHS is becoming more common as cannabis use rises. Patients often cycle through multiple ER visits before diagnosis, and clear treatment protocols can reduce suffering and healthcare costs.

The Bigger Picture

CHS was barely recognized a decade ago and is now a routine ED diagnosis. As cannabis potency and use frequency increase, clinical awareness and standardized treatment protocols become essential.

What This Study Doesn't Tell Us

CHS treatment evidence is largely based on case reports and small studies. No large RCTs exist for most recommended therapies.

Questions This Raises

  • ?Which pharmacological treatments are most effective for acute CHS episodes?
  • ?Can we identify cannabis users at highest risk for developing CHS before it occurs?

Trust & Context

Key Stat:
Evidence Grade:
Review of existing treatment evidence, which is itself largely based on case reports and small studies rather than rigorous trials.
Study Age:
Recent review reflecting current clinical practices for a condition that has become significantly more common in recent years.
Original Title:
Managing cannabinoid hyperemesis syndrome in adult patients in the emergency department.
Published In:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 82(24), 1340-1352 (2025)
Database ID:
RTHC-07967

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What is cannabinoid hyperemesis syndrome?

CHS causes cyclic vomiting and abdominal pain in people who use cannabis heavily and frequently. Symptoms are often temporarily relieved by hot showers but keep recurring until cannabis use stops.

How is CHS treated in the emergency room?

Treatment includes antiemetic medications, topical capsaicin cream, IV fluids, and sometimes benzodiazepines. Hot showers provide temporary relief. The definitive treatment is stopping cannabis use.

Read More on RethinkTHC

Cite This Study

RTHC-07967·https://rethinkthc.com/research/RTHC-07967

APA

Won, Kimberly J; Celmins, Laura. (2025). Managing cannabinoid hyperemesis syndrome in adult patients in the emergency department.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 82(24), 1340-1352. https://doi.org/10.1093/ajhp/zxaf125

MLA

Won, Kimberly J, et al. "Managing cannabinoid hyperemesis syndrome in adult patients in the emergency department.." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025. https://doi.org/10.1093/ajhp/zxaf125

RethinkTHC

RethinkTHC Research Database. "Managing cannabinoid hyperemesis syndrome in adult patients ..." RTHC-07967. Retrieved from https://rethinkthc.com/research/won-2025-managing-cannabinoid-hyperemesis-syndrome

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.